INTRODUCTION
Now a day"s The Pharmaceutical scientists and academicians emphasize on the development in newer drug delivery system which focuses on the drug targeting to achieve high therapeutic effects and minimize adverse effects 1 .The NDDS includes various carriers such as natural and synthetic polymers, polysaccharides, monoclonal antibodies and other biodegradable polymers. It also enlists multi-co mponent structure like liposome, microcapsules, lipoproteins, microparticles, ghost cells and cells.
The cellu lar carrier for drug delivery includes fibroblasts and erythrocytes, leukocytes, platelets and hepatocytes. Resealed erythrocytes are one of the most reviewed systems for targeted delivery because they have one of the most interesting novelties in the development of cellcarrier drug delivery systems. Erythrocytes cells can be loaded with drugs and these can then be released during circulat ion or at targeted sites. Among the cells studied are erythrocytes as these cells offer many advantages including prolonged delivery times and an elevated biocompatibility 2 .
CHARACTERIZATION OF ERYTHROCYTES:
Erythrocytes (RBCs) have the basic function to transport oxygen in the blood. Erythrocytes appear to be circular fro m the top and side view shows that they are actually biconcave discs with diameter of 7.8 μm and thickness aprx 2.2 μm. Th is shape increases the surface area-tovolume rat io of the cell, thus increasing the efficiency of diffusion of O 2 and CO 2 into and out of the cell. Erythrocytes also have a flexible plas ma memb rane which is very useful during drug loading process .
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Figure 1: Erythrocytes as a Carrier
ABS TRACT
The current Pharmaceutical scenario focuses only on the development of targeted and sustained drug delivery systems to achieve required therapeutic concentration with less amount of dose. Among the various carriers used for targeting of the drugs to various body tissues, the encapsulated erythrocytes meet several criteria desirable in clinical applications, among the mo st important being biocompatibility as a carrier and its degradation products. Erythrocytes loaded with drugs and other substances have different release rates. Encapsulated erythrocytes permit controlled release of drug and increase specificity of delivery to the target cells or organs and use of novel routes of drug into cells. Using this technique with a drug present in the extra cellular solution, it is possible to entrap up to 40% of the drug inside the resealed erythrocytes. A variety of bio-macromolecules ranging from 5000 to 600,000 Da can be entrapped into in erythrocytes. The study focused on various methods of Encapsulation of erythrocytes, various techniques of drug loading such as hypo-osmotic-lysis, Chemical perturbation of the membrane, Electroinsertion, Entrapment by endocytosis etc. and it"s applications in various clinical purposes . Key words: Ghost cell, Encapsulated erythrocytes, Phagolysosomes, Reticulo-endothelial system(RES)
SUITAB ILITY OF ERYTHROCYT ES AS DRUG CARRIER
Erythrocytes as a Carrier are one of the innovative drug delivery systems used for years . These are elastic, biconcave shape which enables them to squeeze through narrow capillaries and are selectively removed fro m circulat ion by the macrophages in the Reticulo Endothelial System (RES), hence be able to used in targeting of drugs to RES. The average life span of RBCs is 100-120 days in the circulation so can be used for sustained delivery of therapeutic agents. 8 They posses various characterstics like easy isolation, biocompatibility, specific physico-chemical propert ies, High drug loading efficiency , Lo w leaching or leakage of drug and have enough volumes for loading drug. Eryhrocytes modify the pharmacokinetic and pharmacodynamic parameter of drug.It also minimizes the toxic effect of drug due to fluctuation in concentration to protect the organism. The breakdown products are recycled; hemoglobin is breakdown into globin and heme. Globin degraded to amino acids for amino acid pools in the body, while iron reused in hemoglobin synthesis; therefore, they are well suited to be used as drug carriers.
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ADVANTAGES
OF ENCAPS ULATED ERYTHROCYT ES
Erythrocytes can be used as carriers in two ways; one is that Targeting particular tissue or organ using only the erythrocyte membrane and other is for continuous or sustained release of drugs which provide prolonged drug action. They remain in the circu lation for prolonged periods of time (apprx. 120 days) and release the entrapped drug at a slow and steady rate 3, 4 . Limited potential as carrier to nonphagocytic target tissue.
Given that they are carriers of biological origin, encapsulated erythrocytes may present greater variability and lesser standardisation in their preparation, compared to other carrier systems.
Possibility of clu mping of cells and Dose dump ing may also be there.
The leakage of certain encapsulated substances may be there fro m the loaded erythrocytes.
Several mo lecules may alter the physiology of the erythrocyte.
Liable to biological contamination due to the origin fro m the blood, the equipment used and the loading environment. Rigorous controls are required accordingly for the collection and handling of the erythrocytes.
The storage of the loaded erythrocytes is a problem involving carrier erythrocytes for their possible use in therapeutics. Tests have been performed on their conditioning in suspension in isotonic buffers containing all essential nutrients, as well as in low temperatures, with the addition of nucleosides or chelators, lyophilisation, freezing with glycero l or gel immob ilization.
SOURCE AND ISOLATION OF ERYTHROCYTES
Different mammalians like humen, mon kies, horses, sheeps, goats, rabbits etc., are used for the collection of erythrocytes 14 . Usually to isolate erythrocytes, blood is collected into heparinised tubes by venipuncture. EDTA or heparin can be used as an anticoagulant. Whole blood fro m horse, sheep, goat, dog and rabbit is easily collected through venipuncture. Fresh whole blood is defined as any blood collected and immediately chilled to 4 0C and stored for not more than 2 days. Red blood cells are harvested and washed by centrifugation. After recovering the blood fro m vain puncture and mix with heparin, it is centrifuged at 2000 rp m for 5 min at 4 ±1 0 C. This helps in separation of plasma and Buffy coat. Erythrocytes so obtained are washed three times with buffer solution. These erythrocytes are diluted with phosphate buffer and often stored in acid-citrate-dextrose buffer at 4 0C up to 48 hrs prior to use. 
Species
Washing buffer Centrifugal force(g) Rabbit 10mmol KH2P04 /NaHPO4 500-1000 Dog 15mmol KH2P04 /NaHPO4 500-1000 Hu man 154mmo lNaCl <500 Mouse 10mmol KH2P04 /NaHPO4 100-500 Cow 10-15mmol KH2P04 /NaHPO4 1000 Horse 2 mmo lMg Cl2, 10 g lucose 1000 Sheep 10 mmo l KH2P04 / NaHPO4 500-1000 Pig 10 mmo lKH2P04 /NaHPO4 500-1000
IDEAL PROPERTIES OF DRUGS
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 The Drug should be polar and hydrophilic.
 The drug should resist degradation within erythrocytes.
 It should not have any physical or chemical interaction because drug molecules (non polar and hydrophobic drugs) which interact with the membrane and cause deleterious effects on membrane structure so these are not considered to be appropriate for encapsulation in  It should have well defined pharmacokinetic and pharmacodynamic properties.
 Variety of bio logically active substance i.e. mo l wt ranges from 5000-60,000 Dalton can be entrapped in erythrocytes.
DRUG LOADING METHODS
Various methods can be used to load drugs or other bioactive compounds in erythrocytes, including physical (electrical pulse method) osmosis -based systems, and chemical methods (chemical perturbation of the erythrocytes membrane).
Hypo-os motic lysis method for drug loading
Various methods for Hypo-osmotic lysis are discussed in table below: Table 2 : Hypo-osmotic lysis method for drug loading in erythrocyte 26 -27 2. Chemical perturbation of the membrane [28] [29] According to this method the memb rane permeability of erythrocytes increase when the cells are exposed to certain chemicals. The permeability of erythrocytic membrane increases upon exposure to polyene antibiotic such as amphotericin B. The antineoplastic drug daunomycin was introduced successfully in hu man and mouse erythrocytes. This method has been established by Lin et al for same purpose using halothane. 30 However; this method is not very popular because it induces irreversible destructive changes in the cell membrane.
Electro-insertion or electroencapsulation 31-35
This method is based on the observation that electrical shock brings about irreversible changes in an erythrocyte memb rane 31 . The erythrocyte membrane is opened by a dielectric breakdown. Subsequently, the pores can b e resealed by incubation at 37 0 C in an isotonic mediu m.
The procedure involves suspending erythrocytes in an isotonic buffer in an electrical discharge chamber. A capacitor in an external circuit is charged to a definite voltage and then discharged
Within a definite time interval through cell suspension to produce a square-wave potential . The optimu m intensity of an electric field is between 1-10 kW/cm and optimal discharge time is between 20-160 µs. An inverse relationship exists between the electric-field intensity and the discharge time. The compound to be entrapped is added to the mediu m in which the cells are suspended fro m the commencement of the experiment. The characteristic pore diameter created in the membrane depends upon the intensity of electric field, the discharge time, and the ionic strength of suspending mediu m. The colloidal macro molecu les contents of the cell may lead to cell lysis because of the increase in osmotic pressure. This process can be prevented by adding large molecules (e.g., tetrasaccharide stachyose and bovine serum albu min) and ribonucleose 64 . One advantage of this method is a more uniform d istribution of loaded cells in co mparison with osmotic methods. The main drawbacks are the need for special instrumentation and the sophistication of the process. Entrapment efficiency of this method is close to 35%. Various compounds such as sucrose 36 , urease 39 , methotrexate 47 , isoniazid 43 , human g lycophorin 44 , DNA frag ments, and latex part icles of diameter 0.2 µm can be entrapped within erythrocytes 33 .
Entrapment by endocytosis
-48
In 1975 Schrier et al reported this method by Endocytosis involves the additionof one volume of washed packed erythrocytes to nine volumes of buffer containing 2.5 mM ATP, 2.5 mM MgCl2, and 1mM CaCl2, followed by incubation for 2 min at roo m temperature. The pores created by this method are resealed by using 154 mM of NaCl and incubation at 37 0 C for 2 min . The entrapment of material occurs by endocytosis. The vesicle membrane separates endocytosed material fro m cytoplasm thus protecting it from the erythrocytes and vice-versa. The various candidates for examp le primaquine and related 8-amino-quinolines, vinblastine, chlorpro mazine and related
Method
Procedure % Loadi ng
Advantages Disadvantages
Dilution method
Based upon hypotonic lysis of cells in a solution containing the 1-8% Fastest and simplest, Entrapment capacity low. Drug/enzy me to be entrapped followed by restoration of tonicity especially for low to reseal them and also ability of erythrocytes to undergo mo lecular weight drug. Reversible swelling in a hypotonic solution.
1-8 % Fastest and simp lest, especially for low molecu lar weight drug.
Entrap ment capacity low
Dialysis
It can be carrying out lysis and resealing within a dialysis tube using hypotonic and isotonic solution 30-40 % Better in vivo survival.
Time consuming Preswell dilution
The technique is based upon initial controlled swelling of erythrocytes without lysis by placing them in slightly followed by centrifugation at low "g" to take them up to and good survival in point of lysis. Finally, the addition of small volu me of drug solution to vivo, attain drug loaded resealed erythrocytes.
20-70 %
Good retention of cytoplasm constituents and good survival invivo. 23 Resealed erythrocytes were prepared under isotonic conditions. Haemolysis in isotonic solutions can be achieved both by chemical agent and physical method s. phenothiazines, hydrocortisone, propranolol, tetracaine, and vitamin are entrapped by this method 57 .
Isotonic osmotic lysis
Li pi d Fusion Method
The lipid vesicles containing a drug can be directly fuse to human erythrocytes, which lead to an exchange with a lip id entrapped drug. The methods are useful for entrapping inositol monophasphte to imp rove the oxygen carrying capacity of cells and entrapment efficiency of this method is very lo w (~1%).
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Use of Red Cell Loader
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A method for entrap ment of non diffusible drugs into erythrocytes with equipment called a "red cell loader" .With as little as 50 mL of a blood sample, different biologically active co mpounds were entrapped into erythrocytes within a period of 2 hrs. at roo m temperature under blood banking conditions. The process is based on two sequential hypotonic dilutions of washed erythrocytes followed by concentration with a hemofilter and an isotonic resealing of the cells. There was 30% drug loading with 35-50% cell recovery. The processed erythrocytes had normal survival in vivo. The same cells could be used for targeting by imp roving their recognition by tissue macrophages.
CHARACTERIZATIONS OF ENCAPS ULATED ERTYTHROCYTE
Various characterization parameters are given in table below: Stepwise incubation with isotonic to hypotonic saline solutions and determination of drug and hemoglobin assay Osmotic shock Dilution with distilled water and estimation of drug and hemoglob in Turbulent shock
Passage of cell suspension through 30-gauge hypodermic needle at 10 ml/ min flo w rate and estimat ion of residual drug and hemoglobin, v igorous shaking followed by hemoglobin estimation Erythrocyte sedimentation rate ESR methods
III. Bi ological Characterizati on
Sterility Sterility test Pyrogenicity
Rabbit method, LA L test Animal to xicity Toxicity tests
IV. S afety Considerati ons STEPS TO B E CONS IDERED SAFET Y ISS UE Different blood types
Blood clotting Possible risk of contamination HIV,HBV etc. Changing on physical and possible of clotting Rigidity of membrane mod ification on erythrocytes membranes biochemical characteristics proteins lead to lysis. Extensive biotynilated leads to rapid elimination and kidney problems Changing in pharmacokinetic and pharmacodynamic behaviors of loaded drug Increase the production of unfavorable metabolites
IN-VITRO S TORAGE
32, 34
The most common storage media include Hank"s balanced salt solution and acid-citrate-dextrose at 4 0 C. Cells remain viable in terms of their physiologic and carrier characteristics for at least 2 weeks at this temperature. 62, 63 There are mainly three ways for a drug release fro m the erythrocyte carriers  Phag ocytosis: By the process of phagocytosis normally erythrocyte cells removed fro m the blood circulat ion. The degree of cross linking determines whether liver o r spleen will preferentially remove the cells.
ROUTE OF ADMINIS TRATION
MECHANIS M OF REL EAS E OF LOADED DRUGS
 Diffusion through the membrane of the cells: Diffusion through the memb rane depends on the drug mo lecule penetrate through a lipid bilayer i.e. bioactive compound have lipid solubility.
 Us ing a s pecific trans port system: Most of the drug mo lecules enter cells by a specific membrane protein system because the carriers are proteins with many properties analogous to that of enzymes. 58, 59 Encapsulated erythrocytes have been used as targeted Drug delivery systems for a variety of applications in hu man and veterinary medicine. In vivo application of the drugs loaded erythrocytes are used in two ways as for prolonged drug released and for drug targeting to RES or non RES. The applications of encapsulated erythrocytes are as follows:
APPLICATIONS OF ENCAPS ULATED ERYTHROCYT ES
[I] In vitro
The most frequent in vitro application of RBC is that of micro -in jection. A protein or nucleic acid was injected into eukaryotic cells by fusion process. Similarly, when antibody molecules are introduced using erythrocytic carrier system, they immediately diffuse throughout the cytoplasm. Antibody RBC auto-in jected into living cells has been used to confirm the site of action of frag ment of diphtheria toxin. Antibodies introduced using RBC med iated microinject ion is recorded not to enter the nucleus, thus limit ing the studies to the cytoplasmic level. Encapsulated erythrocytes have been used to facilitate the uptake of enzymes by phagolysosomes for In vitro phagocytosis. Enzy mes content within carrier RBC could be visualized with the help of cytochemical technique. The biochemical defects such as the glucose-6-phosphate dehydrogenase (G6PD) deficiency can be useful tool for discerning the mechanism that eventually causes these effects. Other in vitro tests include utilizat ion of erythrocytes carrier to introduce ribosome inactivating proteins into cells by fusion technique.
[II] In vivo
A. Targeting of bi oacti ve agents to RES
After drug release, remnants of erythrocytes are rapidly cleared fro m circulat ion by phagocytosis. Targeting of the drug minimizes its side effects and the dose to be administered as well as drug utilization. Modifications of erythrocytes membranes by treating them with antibodies, gluteraldehyde, sialic acid, ascorbate, ferrous ion, biotin and sulfhydryl containing substances accelerate their targeting to the liver as well as spleen 18 .
B. Targeting to sites other than RES-rich Organs
Encapsulated Erythrocytes have the ability to deliver a drug or enzyme/proteins to the macrophage-rich organs and these have been used to target non RES organs. 
NOVEL APPROACHES
Erythrosomes are specially designed vesicular systems that are chemically cross-linked to human erythrocytes, support upon which a lipid bilayer is coated. This is achieved by modifying a reverse-phase evaporation technique. These vesicles have been proposed as useful encapsulation systems for macro molecular drugs.
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Nanoerythrosomes are prepared by extrusion of erythrocyte ghosts to produce small vesicles with an average diameter of 100 n m. Daunorubicin was covalently conjugated to nanoerythrosomes using gluteraldehyde spacer. This complex was mo re active than free daunorubicin alone, both in vit ro and in vivo. 55, 56 
CONCLUS ION
This review focuses on the suitability of erythrocytes as biological carriers for therapeutic agents, such as drugs, enzymes and peptides. Encapsulated erythrocytes are effective and safe for targeted and sustained Drug delivery systems with less or no toxicity. Through unexpected twist and turns, encapsulation of erythrocytes became a game changing technology for pharmaceutical sciences. However, the concept needs further optimization to become a routine drug delivery system.
